PTC Therapeutics (PTCT) 2024 Wells Fargo Healthcare Conference summary

Financial performance and outlook

• Raised 2024 revenue guidance to $700–$750 million, reflecting strong performance.

• Ended Q2 with $1.09 billion in cash, maintaining a robust financial position.

• Recent operational changes and royalty monetization improved cash flexibility and reduced debt.

• Commercial infrastructure is in place to support upcoming product launches without significant incremental cost.

• Targeting cash flow break-even, with PKU launch expected to be a key driver.

Regulatory and pipeline updates

• Submitted three FDA approval applications in 2024, including gene therapy for AADC deficiency (FDA action date: Nov 13), sepiapterin for PKU, and resubmission for Translarna.

• NDA for vatiquinone in Friedreich ataxia on track for submission by year-end.

• Interim data for PTC-518 in Huntington’s disease showed strong safety and efficacy signals.

• Top-line results for utreloxastat in ALS expected in Q4.

Translarna regulatory status

• FDA requested minor modifications to clinical study reports for U.S. submission; changes are procedural and expected to be addressed quickly.

• In Europe, undergoing CHMP reexamination with a decision expected around October; EC will decide on market status after CHMP opinion.

• Brazil continues independent review; recent government orders indicate ongoing support.